Navigation Sciences Leadership

Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising through IPOs, private placements, and cross border M&A transactions. His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, ABIOMED, Implant Sciences, Kirschner Orthopedics and ACUFEX MicroSurgical.

Raphael Bueno, MD is the Chief of Thoracic Surgery, the Fredric G Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research, and Co-Director of the Lung Center at the Brigham and Women’s Hospital in Boston. He is also a Professor of Surgery at Harvard Medical School. He leads one of the largest comprehensive divisions of thoracic surgery in the US, which is responsible for nearly 5,000 cases per year. Dr. Bueno’s basic research is focused on developing molecular biomarkers in mesothelioma and lung cancer as well as using genomic strategies to expand therapies for these malignancies. His clinical research is focused on developing new strategies to target small lung nodules and GGOS as well as engineer innovative clinical trials using biological and immune therapies for thoracic cancer.

Dr. Jayender Jagadeesan is an Associate Professor at Harvard Medical School, Research Associate at the Brigham and Women’s Hospital and Associate Member of the Broad Institute.  His research interests include image-guided therapy, surgical navigation, robotics, modeling and control of smart materials, and haptics. Minimally Invasive Surgical devices and applications form his primary research motivation. He is also the technical lead for several surgical procedures in the state-of-the-art Advanced Multimodality Image-guided Operating (AMIGO) suite at BWH.

Giacomo is a member of 23 national committees, 3 hospital committees and 14 professional societies. His previous hospital appointments include UC Davis Medical Center, Yale New Haven Hospital, and UMass Memorial Hospital. Additionally, Giacomo has held Chief Medical Officer positions at several companies, including Z-Medica. Giacomo holds an M.D. and Ph.D. from the University of Milan. His publications include over 80 abstracts, 13 limited dissertations, and over 80 publications in peer review journals.

Carl’s career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. Prior to Mass General Brigham, he served as a Partner at Integral/Analysis Group, a management consultancy focused on innovation strategy. Previously, he was a bench scientist and R&D director at Polaroid Corporation and Hygeia Sciences, where he worked on the development of photographic and clinical diagnostic products. He is an inventor on six U.S. patents. Carl has served on the board of directors of companies spanning multiple biomedical technologies, including: Quosa, Kasalis, Annovation, Combinent Sebacia, Infobionic, QPID Health, LifeImage, Syntimmune, Argo Cardiovascular, Walden Bioscience, Pykus Therapeutics Starlight Cardio, Lyndra, SeQure Dx and the philanthropic Sudanese Education Fund. Carl holds an AB degree from Cornell University and received his Ph.D. in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the in the Harvard-MIT Health Sciences and Technology Division.

Steve is an experienced biotech executive, venture investor, scientist, entrepreneur, and author. Throughout his career he has focused on building companies to translate scientific advances into solutions for patients and providers. He currently advises life science companies on strategy and financings. Previously, he was CEO of Gemphire Therapeutics, Inc., a public biotech which he joined after 10 years as a Managing Director at Excel Venture Management, a firm he co-founded, and which has invested $225M across more than 40 life science companies. At Excel, Steve served as a Board Director of more than a dozen private and public biotech, medtech, diagnostics, and health IT companies, with many successful exits. Prior to Excel, Steve held CEO and CSO positions at two life sciences companies. Steve is currently a Director at Orionis Biosciences and iSpecimen which recently went public on the Nasdaq [ISPC].
Steve began his career as a professor at Harvard Medical School and Brigham & Women’s Hospital, where he published more than 130 scientific papers and was elected a Fellow of the American Association for the Advancement of Science (AAAS) and of the American Heart Association (AHA). He was an advisor to the Innovation Groups at the Cleveland Clinic and Mass General Brigham. He received his Ph.D. from Duke University, post-doctoral training at Yale University, and his B.S. from Union College.

David’s expertise lies in constructing a reliable financial framework to attract funding. He possesses over thirty years of senior financial management experience in various capacities for a variety of medical device, life sciences, and healthcare related companies, including GSI Lumonics, Glympse Bio, Infobionic, Confer Health, and Third Pole Therapeutics.  He is a contributor to the entrepreneurial ecosystem as an active presenter and panelist with, among others, TechStars, MassChallenge, and MIT Enterprise Forum.  David is an active member of the angel investor community and has a BS from Miami University (Ohio), and an MBA from the University of Cincinnati.  David is a licensed Certified Public Accountant (CPA) and is an adjunct instructor in the MBA program teaching Entrepreneurial Finance at Northeastern University.